CROX vs CRSP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CROX and CRSP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CROX and CRSP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Crocs, Inc. designs and sells casual footwear under two brands. The Crocs Brand centers on its signature molded clog made from a proprietary closed-cell resin the company calls Croslite, extended through sandals, sneakers, and the Jibbitz charms that let buyers personalize their shoes. In 2022 Crocs acquired HEYDUDE, a lightweight casual-shoe brand, to add a second growth engine. The company sells through wholesale partners and a growing direct-to-consumer channel that includes its own websites and stores, and it markets heavily through collaborations and celebrity tie-ins. Crocs is known for operating margins well above most footwear peers (about 24% on a trailing basis, with gross margin near 57%), driven by a simple core product, strong pricing, and relatively low marketing spend versus sales.

Full CROX guide

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CROX drivers: High-margin core Crocs Brand; Cash generation and share buybacks.
• CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest risk is that Crocs depends heavily on one iconic product, so a shift in fashion or a fading of the clog trend could hurt demand quickly, and single-product concentration makes the stock sensitive to sentiment about the brand's staying power. For CRSP, the commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $13.4 million over the twelve months to June 2026.

Pick CROX if you believe its drivers more; CRSP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CROX and CRSP guides.

CROX. Even after a roughly 44% gain in 2026, Crocs trades near 11 times trailing and 8 times forward earnings, cheap for a business with mid-20s operating margins, because the market still questions how long single-product profitability lasts and how much HEYDUDE will cost. Analysts' mean target is about $138.75 across 12 covering firms. The October 29, 2026 Q3 report (consensus ~$1.0 billion revenue, $3.30 EPS) will show whether the second-quarter return to growth holds.

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based multiples like P/E are negative and not analytically useful; the company is better evaluated on cash runway, Casgevy adoption, and the risk-adjusted value of its pipeline. Market cap of about $4.9 billion less roughly $1.6 billion of net cash leaves an enterprise value near $3.3 billion, which reflects significant execution uncertainty. Targets remain widely spread, from UBS at $52 to a consensus mean near $86.

Headline figures (approximate, October 2026): CROX shows revenue (ttm) ~$4.05 billion; Q2 2026 ~$1.18 billion, up ~2.6% year over year, margins (ttm) Gross ~57%, operating ~24%, net ~15%, net income / eps (ttm) ~$593 million; trailing EPS ~$11.41, p/e (trailing / forward) ~10.9x / ~8.3x; CRSP shows revenue (ttm to jun 30, 2026) ~$13.4 million (Q2 2026 ~$10.2 million), revenue (full year 2025) ~$3.5 million, net loss (ttm) ~$451 million; Q2 2026 ~$91 million, eps (q2 2026, actual vs estimate) -$0.94 vs -$1.18.

CROX and CRSP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CROX and CRSP exposure against your real portfolio. It is not an investment adviser.